U.S. Multiple Sclerosis Drugs Market to Reach USD 20.89 Billion and Europe USD 15.51 Billion by 2035 as Monoclonal Antibody Therapies and Personalized Neurology Solutions Drive Demand.

Austin, United States, Sept. 01, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Multiple Sclerosis Drugs Market was valued at USD 21.70 Billion in 2025 and is expected to reach USD 52.82 Billion by 2035, advancing at a CAGR of 9.31% across 2026-2035. The growth will be fueled by an increasing burden of autoimmune neurologic diseases, advances in neuroimaging diagnosis, and continuous development of disease modifying therapies. The approach to treatment is moving towards early management which prevents progression instead of symptom management. Drug developers are still pushing ahead with monoclonal antibodies, oral medications, and immunotherapies which are more effective and convenient.

Advancements in precision medicine, AI-based disease surveillance, biomarker-based therapy choice, and digital neurology technologies are changing the treatment of MS. The use of AI in MRIs, remote disease surveillance, and predictions is aiding neurologists in personalizing treatments and monitoring the disease activity. Increased investment is being made in clinical trials on progressive multiple sclerosis.


Download the Multiple Sclerosis Drugs Market Sample Report: https://www.snsinsider.com/sample-request/10658

Multiple Sclerosis Drugs Market Key Highlights

  • Market size, 2025: USD 21.70 Billion
  • Market size, 2026E: USD 23.71 Billion
  • Market forecast, 2035: USD 52.82 Billion
  • CAGR: 9.31% from 2026 to 2035
  • Largest region: North America, approximately 46.00% share in 2025
  • Fastest-growing region: Asia Pacific, approximately 12.84% CAGR
  • Largest drug class: Monoclonal antibodies, approximately 39.00% share in 2025
  • Fastest-growing drug class: Corticosteroids, approximately 11.20% CAGR
  • Largest disease type: Relapsing-remitting multiple sclerosis (RRMS), approximately 67.00% share in 2025
  • Fastest-growing disease type: Primary progressive multiple sclerosis (PPMS), approximately 12.75% CAGR
  • Largest route of administration: Oral, approximately 42.00% share in 2025
  • Fastest-growing route of administration: Intravenous infusion, approximately 11.85% CAGR
  • Largest end user: Hospitals, approximately 39.00% share in 2025
  • Fastest-growing end user: Retail & specialty pharmacies, approximately 10.60% CAGR

Market Relevance

Development of MS drugs has emerged as an essential aspect of contemporary neurology due to the need for systematic and evidence-based approaches to managing a chronic autoimmune disorder. Increased numbers of diagnosis cases, as well as advanced diagnostic techniques, have contributed to the growth of the target market for treatments.

Multiple Sclerosis Drugs Market Overview

The market includes therapies through monoclonal antibodies, oral disease-modifying drugs, corticosteroids, and other immuno-therapies by oral administration, intravenous administration, and other means of administration. High efficacy biologicals have gained acceptance because of the increased importance placed by neurologists on relapse prevention rather than simply symptom treatment.

Strategic Market Outlook

Opportunities exist in the personalized treatment of diseases through precision medicine and identification of appropriate treatment based on the use of genomics and AI for disease prediction, thus helping the neurologists choose treatment that is effective and has fewer side effects. Other opportunities include the emerging economies within the Asian Pacific region, Latin America, and the Middle East due to the improvement in healthcare services and diagnostics.

On the other hand, the high cost of biological drugs poses a challenge because of the complicated process of production, clinical studies, and long-term monitoring of safety. This challenge is experienced even where there are no insurance programs for drug costs in some countries.

Multiple Sclerosis Drugs Market Regional Analysis

North America held the largest share at approximately 46.00% in 2025, with the United States contributing around 94.00% of regional revenue, backed by a high prevalence of diagnosed cases, advanced healthcare infrastructure, and rapid adoption of new treatments.

The U.S. Multiple Sclerosis Drugs Market was valued at USD 9.38 Billion in 2025 and is projected to reach approximately USD 20.885 Billion by 2035, growing at a CAGR of 8.32% from 2026 to 2035, supported by strong disease awareness, favorable reimbursement, and quick uptake of novel biologics and next-generation treatments.

The Europe Multiple Sclerosis Drugs Market was valued at USD 6.51 Billion in 2025 and is expected to reach USD 15.51 Billion by 2035, expanding at a CAGR of 9.00% from 2026 to 2035. Germany accounted for approximately 31.00% of European revenue in 2025, supported by strong disease awareness and favorable reimbursement across Western Europe.

The Asia-Pacific region is projected to be the fastest-growing, expanding at approximately 12.84% CAGR, with China contributing around 16.00% of regional revenue in 2025 amid improving healthcare infrastructure, rising awareness, and growing healthcare spending across China, Japan, South Korea, and India.

Middle East & Africa: Expected to grow steadily, with the UAE contributing approximately 4.00% of regional revenue in 2025, supported by improving healthcare infrastructure and rising disease awareness.

Latin America: Also expected to see steady growth, with Brazil contributing approximately 3.00% of regional revenue in 2025, driven by expanding healthcare access and rising adoption of disease-modifying drugs across Brazil, Mexico, Argentina, and Colombia.

Buy the Multiple Sclerosis Drugs Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/10658

Multiple Sclerosis Drugs Market Segment Analysis

By Drug Class: Monoclonal antibodies led with approximately 39.00% share in 2025, reflecting physician preference for high-efficacy biologics. Corticosteroids are the fastest-growing class, at approximately 11.20% CAGR.

By Disease Type: Relapsing-remitting MS (RRMS) accounted for approximately 67.00% of revenue in 2025 as the most commonly diagnosed form with the widest range of approved therapies. Primary progressive MS (PPMS) is growing fastest, at approximately 12.75% CAGR, supported by expanding progressive-disease research.

By Route of Administration: Oral therapies led with approximately 42.00% share in 2025 on patient preference for convenient, adherence-friendly treatment. Intravenous infusion is the fastest-growing route, at approximately 11.85% CAGR, driven by rising use of potent biologics in aggressive cases.

By End User: Hospitals held the largest share at approximately 39.00% in 2025, central to diagnosis and infusion-based therapy. Retail & specialty pharmacies are the fastest-growing channel, at approximately 10.60% CAGR, as oral-therapy adoption and demand for convenient access rise.

Multiple Sclerosis Drugs Market Key Trends

  • Rising use of high-efficacy monoclonal antibody treatments for relapsing multiple sclerosis
  • Increasing integration of AI-based neurological monitoring with precision-medicine approaches
  • Growing preference for oral disease-modifying therapies that improve patient adherence
  • Expansion of clinical research focused on progressive multiple sclerosis and neuroprotection
  • Continued investment in biomarker-driven personalized treatment and digital neurology tools

Competitive Landscape

The Multiple Sclerosis Drugs Market comprises major international players from pharmaceuticals, biologics, and neurology segments. Competition within the market lies in high-efficacy biologics, novel formulations, and increased research for the progressive types of diseases.

In 2026, the U.S. FDA approved Roche/Genentech's Ocrevus Zunovo for relapsing and primary progressive MS, a subcutaneous formulation with significantly shorter administration time than IV infusion. Companies have also expanded research into immune-targeted biologics, remyelination approaches, and neuroprotective treatments, while 2025 saw rising clinical-trial investment in B-cell and immune-pathway therapies and accelerating adoption of remote monitoring and AI-assisted imaging in MS care.

Major key players include

  • Roche Holding AG
  • Biogen Inc.
  • Novartis AG
  • Merck KGaA
  • Sanofi
  • Bristol Myers Squibb
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Viatris Inc.
  • AbbVie Inc.
  • Pfizer Inc.
  • Alkermes plc
  • TG Therapeutics
  • Actelion Pharmaceuticals Ltd.
  • GlaxoSmithKline plc
  • Acorda Therapeutics Inc.
  • EMD Serono Inc.
  • Genentech, Inc.
  • Horizon Therapeutics plc

Explore the Complete Multiple Sclerosis Drugs Market Report: https://www.snsinsider.com/reports/multiple-sclerosis-drugs-market-10658

CONTACT: About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com